Literature DB >> 10488697

The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies.

H F Löhr1, D Schmitz, M Arenz, S Weyer, G Gerken, K H Meyer zum Büschenfelde.   

Abstract

BACKGROUND/AIMS: Cytotoxic T lymphocytes have been demonstrated in peripheral blood and liver tissue of patients with chronic hepatitis C virus infection, but their significance for viral clearance is unknown. Therefore, we analyzed hepatitis C virus-specific cytotoxic T lymphocyte precursor frequencies in chronic hepatitis C virus carriers during interferon-alpha treatment.
METHODS: Blood mononuclear cells or CD8+ T cells from HLA-A2 positive and negative patients and controls were analyzed in chromium-release assays using a panel of 18 synthetic peptides from the HCV core, E1 and NS4 antigens bearing HLA-A2 binding motifs. Specific cytotoxic T lymphocyte precursor frequencies were studied within CD8+ T cells derived from interferon-alpha-treated patients using a TNF-alpha-based ELISPOT assay and compared to viremia levels.
RESULTS: T cells from 16 of 24 HLA-A2+ but none of the six HLA-A2- patients with chronic hepatitis C and six HLA-A2+ healthy controls lysed targets pulsed with peptide cocktails. Fine specificity revealed four very immunogenic epitopes in the core (C36-44, C132-140) and the envelope regions (E332-340, E363-372). Cytotoxic T lymphocyte precursor frequencies were prospectively analyzed in 11 interferon-alpha-treated HLA-A2+ hepatitis C virus patients. Four sustained and two transient therapy responders showed lower pretreatment viremia levels and significantly higher specific cytotoxic T lymphocyte precursor frequencies during viral clearance compared to five therapy non-responders and untreated controls.
CONCLUSIONS: The quantitative induction of HLA-class I restricted responses by interferon-alpha could contribute to a beneficial outcome of hepatitis C virus infections. Furthermore, it appears that the balance between viral load and specific cellular immune responses is critical for successful viral clearance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488697     DOI: 10.1016/s0168-8278(99)80030-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

1.  Interferon-gamma is produced by CD8 T cells in response to HLA-A24-restricted hepatitis C virus epitopes after sustained virus loss.

Authors:  K Kobayashi; M Ishii; M Shiina; Y Ueno; Y Kondo; A Kanno; Y Miyazaki; T Yamamoto; T Kobayashi; H Niitsuma; Y Kikumoto; H Takizawa; T Shimosegawa
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

2.  Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans.

Authors:  Mark A A Claassen; Robert J de Knegt; Harry L A Janssen; André Boonstra
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

3.  Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities.

Authors:  Georg M Lauer; Kei Ouchi; Raymond T Chung; Tam N Nguyen; Cheryl L Day; Deborah R Purkis; Markus Reiser; Arthur Y Kim; Michaela Lucas; Paul Klenerman; Bruce D Walker
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  Hla-Cw7 allele as predictor of favorable therapeutic response to interferon-alpha in patients with chronic hepatitis C.

Authors:  Ivo Ivić; Nikola Bradarić; Neira Puizina-Ivić; Dragan Ledina; Boris Luksić; Roko Martinić
Journal:  Croat Med J       Date:  2007-12       Impact factor: 1.351

5.  Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.

Authors:  Joana Caetano; António Martinho; Artur Paiva; Beatriz Pais; Cristina Valente; Cristina Luxo
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

6.  Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice.

Authors:  Leila Pishraft Sabet; Tahereh Taheri; Arash Memarnejadian; Talat Mokhtari Azad; Fatemeh Asgari; Ramin Rahimnia; Seyed Moayed Alavian; Sima Rafati; Katayoun Samimi Rad
Journal:  Hepat Mon       Date:  2014-10-15       Impact factor: 0.660

7.  Modulation of hepatitis C virus core DNA vaccine immune responses by co-immunization with CC-chemokine ligand 20 (CCL20) gene as immunoadjuvant.

Authors:  Christine Hartoonian; Zargham Sepehrizadeh; Mehdi Mahdavi; Arash Arashkia; Yon Suk Jang; Maasoumeh Ebtekar; Mojtaba Tabatabai Yazdi; Babak Negahdari; Azita Nikoo; Kayhan Azadmanesh
Journal:  Mol Biol Rep       Date:  2014-06-28       Impact factor: 2.742

8.  Enhancement of Immune Responses by Co-delivery of CCL19/MIP-3beta Chemokine Plasmid With HCV Core DNA/Protein Immunization.

Authors:  Christine Hartoonian; Zargham Sepehrizadeh; Mojtaba Tabatabai Yazdi; Yong Suk Jang; Lida Langroudi; Parisa Amir Kalvanagh; Babak Negahdari; Ali Karami; Massoumeh Ebtekar; Kayhan Azadmanesh
Journal:  Hepat Mon       Date:  2014-03-01       Impact factor: 0.660

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.